Clinical study on the immediate of Shexiang Tongxin dropping pill on coronary slow blood flow and its long-term effect

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003534

Enrollment

Unknown

Registered

2020-08-02

Start date

2020-09-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Slow Flow

Interventions

Control group:sublingual placebo 4 capsules 5 min after inclusion of coronary angiography, followed by oral placebo 2 capsules 3 times a day, a total of 3 months.

Trial Group:Four tablets of Shexiang Tongxin drop pills were taken under the tongue min and then coronary angiography was performed again, and then 2 tablets of Shexiang Tongxin drop pills were taken

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as CSF; 2. TCM syndrome belongs to heart blood stasis obstruction; 3. Aged between 18~80 years; 4. Sign informed consent. Note: the diagnosis of heart blood stasis syndrome refers to the diagnostic standard issued by the professional committee of promoting blood circulation and removing blood stasis of the Chinese Society of Integrated Chinese and Western Medicine in 2016. (1) Tongue purple dark or have ecchymosis, stasis point; (2) Lips purple or dark; (3) Sublingual choroid varicose.

Exclusion criteria

Exclusion criteria: 1. Patients with acute myocardial infarction or previous history of myocardial infarction; 2. Had a history of coronary intervention; 3. Patients with valvular heart disease, cardiomyopathy, coronary artery bridge, aortic dissection, acute pericarditis, acute pericarditis, cardiac insufficiency; 4. With uncontrolled grade 3 hypertension (systolic blood pressure >= 180 mmHg and/or diastolic blood pressure 110 mmHg), severe cardiopulmonary insufficiency, severe arrhythmia, serious essential diseases such as liver, kidney and hematopoietic system, or serious diseases affecting their survival (such as tumors) and mental patients; 5. Liver and kidney function Abnormal (ALTASTScr 1.5 times above the upper limit of normal reference range); 6. Allergic constitution, or to a variety of drugs food allergies, or known to test drugs (including their components) allergies; 7. Pregnant or lactating women with a pregnancy plan; 8. Abnormal thyroid function; 9. Patients who participated in other clinical trials within 1 month.

Design outcomes

Primary

Measure	Time frame
Cardiac radionuclide score;ET-1;Lp-PLA2;Long-term efficacy;CD63;Immediate change of coronary blood flow;iNOs;hs-CRP;Blood stasis syndrome score;Coagulation function;CD62;IL-1;IL-6;NO;Corrected TIMI blood flow frame count;TNF-a;adropin;eNOs;	—

Secondary

Measure	Time frame
Urine routine;NT-proBNP;Blood routine;Color Doppler echocardiography;Stool routine;12-lead electrocardiogram;Liver and kidney function;Blood lipid;Heart damage (TnI\CK-MB\Myo);	—

Countries

China

Contacts

Public ContactLijing Zhang

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

dzmyyccu@163.com+86 13501214395

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026